Akero Therapeutics, Inc. (AKRO)

Akero Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	36.19	31.07	29.87	19.13	15.27	8.61
Research & Development	198	141.8	85.28	81.76	64.88	37.05
Operating Expenses	234.18	172.87	115.16	100.89	80.15	45.65
Operating Income	-234.18	-172.87	-115.16	-100.89	-80.15	-45.65
Interest Expense	-4.01	-3.1	-0.74	-	-	-
Interest & Investment Income	30.28	24.21	3.86	0.11	0.95	1.9
EBT Excluding Unusual Items	-207.91	-151.76	-112.03	-100.78	-79.21	-43.76
Pretax Income	-204.18	-151.76	-112.03	-100.78	-79.21	-43.76
Net Income	-204.18	-151.76	-112.03	-100.78	-79.21	-43.76
Net Income to Common	-204.18	-151.76	-112.03	-100.78	-79.21	-43.76
Shares Outstanding (Basic)	60	53	39	35	31	15
Shares Outstanding (Diluted)	60	53	39	35	31	15
Shares Change (YoY)	30.11%	34.84%	11.94%	10.69%	108.77%	14474.75%
EPS (Basic)	-3.40	-2.89	-2.87	-2.89	-2.52	-2.90
EPS (Diluted)	-3.40	-2.89	-2.87	-2.89	-2.52	-2.90
Free Cash Flow	-191.94	-145.37	-92.52	-79.68	-70.95	-35.63
Free Cash Flow Per Share	-3.20	-2.77	-2.37	-2.29	-2.26	-2.36
EBITDA	-234.17	-172.84	-115.11	-100.85	-80.14	-
D&A For EBITDA	0.01	0.03	0.04	0.04	0.02	-
EBIT	-234.18	-172.87	-115.16	-100.89	-80.15	-45.65

Source: S&P Capital IQ. Standard template. Financial Sources.